CORDIS
EU research results

CORDIS

English EN

Elucidating Pathways of Steatohepatitis

Objective

Strongly associated with the epidemics of obesity and type 2 diabetes mellitus (T2DM) that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease in the aging population of Europe. NAFLD is a spectrum of hepatic fat accumulation (steatosis); steatosis plus inflammation (non-alcoholic steatohepatitis, NASH); fibrosis/cirrhosis; and hepatocellular carcinoma in the absence of high alcohol consumption.
Up to 30% of the EU population have NAFLD, which will be the main aetiology underlying liver transplants by 2020. However, NAFLD is characterized by substantial inter-patient variability in severity and rate of progression. What determines this is unknown. A large population is at risk, but only some experience morbidity. NAFLD severity is currently best assessed by liver biopsy, an invasive, costly and risky procedure - factors that hinder treatment. There is a need to understand the biological and environmental factors that drive inter-patient variability and to develop robust and more acceptable methods for diagnosis, risk stratification and therapy so that effective medical care may be targeted to those that will benefit most.
The overall EPoS concept is that improved understanding of pathogenic processes and drivers of disease progression will best be achieved when multiple ‘omics’ approaches are applied to a single cohort of patients to build a multi-dimensional record of how systems are perturbed across the entire spectrum of disease. NAFLD sits at the intersection of key biological processes: carbohydrate/lipid homeostasis, immune/inflammatory activation, wound healing/fibrosis and cancer biology. Once completed, EPoS promises to deliver a substantial and definitive atlas of pathophysiological variation across a spectrum of progressive liver disease. Translation of these findings will therefore impact on closely related pathologies including T2DM and cardiovascular disease.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE

Address

Kings Gate
Ne1 7ru Newcastle Upon Tyne

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 1 629 948,50

Participants (11)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 517 990

INST CARDIOMETABOLISME NUTRITION ICAN

France

EU Contribution

€ 1 012 317,50

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 130 000

Steno Diabetes Center A/S

Denmark

EU Contribution

€ 184 256

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 662 635

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 533 065

UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ

Germany

EU Contribution

€ 261 000

NORDIC BIOSCIENCE A/S

Denmark

EU Contribution

€ 187 500

NORDIC BIOSCIENCE COMPOUND DEVELOPMENT A/S

Denmark

IXSCIENT LIMITED

United Kingdom

EU Contribution

€ 298 750

OREBRO UNIVERSITY

Sweden

EU Contribution

€ 568 059

Project information

Grant agreement ID: 634413

Status

Ongoing project

  • Start date

    1 May 2015

  • End date

    31 October 2019

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 6 173 021

  • EU contribution

    € 5 985 521

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom